OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
VEEV
Veeva Systems Inc.
VEEV has a slight edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VEEV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
VEEV's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over VEEV in the historical PE scenario, which offers more potential upside but is not a forecast.
VEEV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $302 | — |
| Current | 50x | $302 | — |
| Cheap | 53x | $324 | +7.1% |
| Fair | 64x | $389 | +29% |
| Expensive | 115x | $700 | +131% |
Historical ranges are pointers, not guarantees.
VEEV's PE is in its cheap range at 50x. If earnings grow as analysts expect, today's price would be 30x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over VEEV on the outlook, with more favorable profitability expectations.
VEEV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for VEEV, with profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
VEEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.93 | +63% |
| Q3 2026 | $6.11 | +26% |
| Q2 2026 | $5.64 | +20% |
| Q1 2026 | $5.44 | +26% |
| Q4 2025 | $5.13 | +27% |
| Q3 2025 | $4.86 | +30% |
| Q2 2025 | $4.71 | +39% |
| Q1 2025 | $4.32 | +34% |
| Q4 2024 | $4.05 | +17% |
VEEV has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VEEV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
VEEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $928M | +18% |
| Q2 2026 | $882.9M | +16% |
| Q1 2026 | $836M | +16% |
| Q4 2025 | $811.2M | +16% |
| Q3 2025 | $789.1M | +17% |
| Q2 2025 | $759M | +17% |
| Q1 2025 | $720.9M | +14% |
| Q4 2024 | $699.2M | +13% |
VEEV's revenue has grown year over year every quarter since late 2020: $928M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +4.8 points |
| Q2 2026 | 31% | +0.1 points |
| Q1 2026 | 29% | +3.3 points |
| Q4 2025 | 30% | +3.8 points |
| Q3 2025 | 25% | +0.2 points |
| Q2 2025 | 31% | +6.9 points |
| Q1 2025 | 26% | +4.7 points |
| Q4 2024 | 26% | +5.1 points |
VEEV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
VEEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $238.7M | +0.1% |
| Q2 2026 | $1.1B | +28% |
| Q1 2026 | $106.8M | +54% |
| Q4 2025 | $192.8M | +17% |
| Q3 2025 | $238.4M | +157% |
| Q2 2025 | $877.2M | +15% |
| Q1 2025 | $69.5M | +20% |
| Q4 2024 | $164.1M | +99% |
VEEV has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VEEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -932K shares |
| 1 year | -1.6% | -2.6M shares |
| 3 years | +1.1% | +1.8M shares |
| 5 years | +1.4% | +2.3M shares |
| Available history | +4% | +6.3M shares |
VEEV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $245.7M |
| Q2 2026 | $226.9M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VEEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -1.6x | Net Cash |
| Q4 2023 | -1.8x | Net Cash |
| Q3 2023 | -1.8x | Net Cash |
| Q2 2023 | -2.6x | Net Cash |
| Q1 2023 | -1.8x | Net Cash |
| Q4 2022 | -1.7x | Net Cash |
| Q3 2022 | -2.2x | Net Cash |
| Q2 2022 | -2.3x | Net Cash |
VEEV has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VEEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.5 | Neutral |
| Stochastic | 82.7 | Overbought |
VEEV's weekly RSI is 66 (neutral) and its Stochastic is 83 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over VEEV on valuation relative to its sector.
VEEV PE vs Healthcare Sector
| Metric | VEEV | Sector median | Relative |
|---|---|---|---|
| PE | 50x | 26x | 91% above |
| PE % | 13 | 29 | 16 pts below |
VEEV is trading at 50x earnings, a 91% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
VEEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $300.3 | 0.7% above |
| 20 week MA | $258.4 | 17% above |
| 50 week MA | $215.6 | 40% above |
| 100 week MA | $236.1 | 28% above |
| 200 week MA | $216.7 | 40% above |
VEEV is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VEEV on returns for 2026, with the stronger performance.
VEEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $140.7 | $287.6 | +104% |
| 2021 | $287.6 | $260.6 | -9.4% |
| 2022 | $260.6 | $160.8 | -38% |
| 2023 | $160.8 | $192.5 | +20% |
| 2024 | $192.5 | $214.0 | +11% |
| 2025 | $214.0 | $224.7 | +5% |
| 2026 YTD | $224.7 | $302.4 | +35% |
VEEV has finished higher in four of the last six years. It's up 35% so far in 2026.